PMV PHARMACEUTICALS, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
PMV PHARMACEUTICALS, INC. (PMVP) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $767.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-14
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-06-30 was $382.00K, a 47.24% decline year-over-year.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was $385.00K, a 54.17% decline year-over-year.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-12-31 was $513.00K, a 54.68% decline year-over-year.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $694.00K, a 43.81% decline year-over-year.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $2.77M, a 48.41% decline from fiscal 2024.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was $5.37M, a 0.28% decline from fiscal 2023.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $5.39M, a 757.64% increase from fiscal 2022.
- PMV PHARMACEUTICALS, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was $628.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $382.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $767.00K 10-Q · filed 2026-08-14 | $1.28M derived: sum of 3 quarters · filed 2026-08-14 | $1.97M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2026-03-31 | $385.00K 10-Q · filed 2026-05-12 | $898.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.59M derived: sum of 3 quarters · filed 2026-05-12 | $2.32M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-12-31 | $513.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.21M derived: sum of 2 quarters · filed 2026-03-06 | $1.93M derived: sum of 3 quarters · filed 2026-08-14 | $2.77M 10-K · filed 2026-03-06 | |||
| 2025-09-30 | $694.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.42M derived: sum of 2 quarters · filed 2026-08-14 | $2.26M 10-Q · filed 2025-11-12 | $3.39M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-06-30 | $724.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.56M 10-Q · filed 2026-08-14 | $2.70M derived: sum of 3 quarters · filed 2026-08-14 | $3.93M derived: sum of 4 quarters · filed 2026-08-14 | |||
| 2025-03-31 | $840.00K 10-Q · filed 2026-05-12 | $1.97M derived: sum of 2 quarters · filed 2026-05-12 | $3.21M derived: sum of 3 quarters · filed 2026-05-12 | $4.58M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | $1.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $2.37M derived: sum of 2 quarters · filed 2026-03-06 | $3.74M derived: sum of 3 quarters · filed 2026-03-06 | $5.37M 10-K · filed 2026-03-06 | |||
| 2024-09-30 | $1.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $2.61M derived: sum of 2 quarters · filed 2025-11-12 | $4.24M 10-Q · filed 2025-11-12 | $6.11M derived: sum of 4 quarters · filed 2026-03-06 | |||
| 2024-06-30 | $1.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $3.00M 10-Q · filed 2025-08-07 | $4.88M derived: sum of 3 quarters · filed 2026-03-06 | $6.72M derived: sum of 4 quarters · filed 2026-03-06 | |||
| 2024-03-31 | $1.63M 10-Q · filed 2025-05-09 | $3.50M derived: sum of 2 quarters · filed 2026-03-06 | $5.34M derived: sum of 3 quarters · filed 2026-03-06 | $6.30M derived: sum of 4 quarters · filed 2026-03-06 | |||
| 2023-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $3.71M derived: sum of 2 quarters · filed 2026-03-06 | $4.67M derived: sum of 3 quarters · filed 2026-03-06 | $5.39M 10-K · filed 2026-03-06 | |||
| 2023-09-30 | $1.84M 10-Q · filed 2023-11-09 | $2.80M derived: sum of 2 quarters · filed 2024-08-08 | $3.51M 10-Q · filed 2024-11-07 | $4.04M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-06-30 | $958.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.67M 10-Q · filed 2024-08-08 | $2.20M derived: sum of 3 quarters · filed 2025-03-03 | $2.42M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2023-03-31 | $712.00K 10-Q · filed 2024-05-09 | $1.24M derived: sum of 2 quarters · filed 2025-03-03 | $1.47M derived: sum of 3 quarters · filed 2025-03-03 | $1.54M derived: sum of 4 quarters · filed 2025-03-03 | |||
| 2022-12-31 | $526.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $754.00K derived: sum of 2 quarters · filed 2025-03-03 | $826.00K derived: sum of 3 quarters · filed 2025-03-03 | $628.00K 10-K · filed 2025-03-03 | |||
| 2022-09-30 | $228.00K 10-Q · filed 2023-11-09 | -$228.00K 10-Q · filed 2022-11-08 | $300.00K derived: sum of 2 quarters · filed 2023-11-09 | $102.00K 10-Q · filed 2023-11-09 | $155.00K derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2022-06-30 | $72.00K 10-Q · filed 2022-08-09 | $126.00K 10-Q · filed 2023-08-09 | -$73.00K derived: sum of 3 quarters · filed 2024-02-29 | -$200.00K derived: sum of 4 quarters · filed 2024-02-29 | |||
| 2022-03-31 | -$54.00K 10-Q · filed 2023-05-10 | $54.00K 10-Q · filed 2022-05-10 | -$145.00K derived: sum of 2 quarters · filed 2024-02-29 | -$272.00K derived: sum of 3 quarters · filed 2024-02-29 | -$107.00K derived: sum of 4 quarters · filed 2024-02-29 | ||
| 2021-12-31 | -$91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$218.00K derived: sum of 2 quarters · filed 2024-02-29 | -$53.00K derived: sum of 3 quarters · filed 2024-02-29 | -$550.00K 10-K · filed 2024-02-29 | $550.00K 10-K · filed 2022-03-01 | ||
| 2021-09-30 | -$127.00K 10-Q · filed 2022-11-08 | $127.00K 10-Q · filed 2021-11-12 | $38.00K derived: sum of 2 quarters · filed 2022-11-08 | -$459.00K 10-Q · filed 2022-11-08 | $459.00K 10-Q · filed 2021-11-12 | -$99.00K derived: sum of 4 quarters · filed 2023-03-01 | |
| 2021-06-30 | $165.00K 10-Q · filed 2022-08-09 | $332.00K 10-Q · filed 2022-08-09 | $28.00K derived: sum of 3 quarters · filed 2023-03-01 | $34.00K derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2021-03-31 | $167.00K 10-Q · filed 2022-05-10 | -$137.00K derived: sum of 2 quarters · filed 2023-03-01 | -$131.00K derived: sum of 3 quarters · filed 2023-03-01 | -$72.00K derived: sum of 4 quarters · filed 2023-03-01 | |||
| 2020-12-31 | -$304.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$298.00K derived: sum of 2 quarters · filed 2023-03-01 | -$239.00K derived: sum of 3 quarters · filed 2023-03-01 | -$152.00K 10-K · filed 2023-03-01 | $152.00K 10-K · filed 2021-03-03 | ||
| 2020-09-30 | $6.00K 10-Q · filed 2021-11-12 | $65.00K derived: sum of 2 quarters · filed 2021-11-12 | $152.00K 10-Q · filed 2021-11-12 | $192.00K derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | $59.00K 10-Q · filed 2021-08-13 | $147.00K 10-Q · filed 2021-08-13 | $186.00K derived: sum of 3 quarters · filed 2022-03-01 | $199.00K derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | $87.00K 10-Q · filed 2021-05-14 | $127.00K derived: sum of 2 quarters · filed 2022-03-01 | $140.00K derived: sum of 3 quarters · filed 2022-03-01 | ||||
| 2019-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $53.00K derived: sum of 2 quarters · filed 2022-03-01 | $62.00K 10-K · filed 2022-03-01 | ||||
| 2019-09-30 | $13.00K 10-Q · filed 2020-11-13 | $22.00K 10-Q · filed 2020-11-13 | |||||
| 2018-12-31 | $319.00K 10-K · filed 2021-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |